ScienceAlert on MSN3d
Scientists May Have Discovered a Natural Alternative to Ozempic
Scientists may have identified a way to naturally regulate blood sugar levels and sugar cravings in a similar fashion to ...
Business Insider1mon
CORXEL Acquires Worldwide (excluding Greater China) Rights to an Oral Small Molecule GLP-1 RA for the Treatment of Obesity and Diabetes
today announced the acquisition of CX11 (also known as VCT220), an oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA), for worldwide (excluding Greater China) development and ...
Medscape8d
Glucagon Prescriptions Still Fall Short of Meeting Demand
Glucagon prescriptions for severe hypoglycemia in Medicaid initially decreased from 2012 to 2018 but increased between 2019 and 2023 following the introduction of newer products. Glucagon ...
JPM 2025: WuXi AppTec rebuffs concern about lower GLP-1 demand after Lilly’s low revenue forecast
Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.
BioWorld1mon
Structure Therapeutics selects lead oral DACRA for obesity
Structure Therapeutics Inc. has selected a lead oral small-molecule amylin receptor agonist ... that is being evaluated for use either alone or in combination with glucagon-like peptide-1 (GLP-1) ...